NeuroDR
Deep Reasoning Ai, Inc. · Decision date Oct 7, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for NeuroDR, a 510(k) submitted by Deep Reasoning Ai, Inc. under K262134, with a decision date of October 7, 2026. The device is classified under 21 CFR 892.2050 (medical image management and processing system), product code QIH, in the radiology panel. SESE means the submission was cleared as substantially equivalent; it is not a PMA approval.
NeuroDR is described as a fully automated AI/ML-enabled software device that takes CTA head and neck DICOM data and produces maximum intensity projection, volume rendered, and curved planar reformat outputs returned as DICOM series for physician review. The summary names Rapid Neuro3D (K243350) as the predicate and states the indications and technological characteristics are equivalent. The summary does not provide clinical performance results, and the source does not establish current labeling beyond the documents shown.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Oct 7, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262134
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Deep Reasoning Ai, Inc.
- Product code
- QIH
- Decision code
- SESE
- Decision date
- Oct 7, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Automated Radiological Image Processing Software.
- Applicant
- Deep Reasoning Ai, Inc.
- Product code
- QIH
- FDA device class
- 2
FDA decision timeline
K262134 received
Application receipt date recorded by FDA.
K262134 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QIH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Clever OneK260372 | Ewoosoft Co., Ltd. | 510(k) clearance | Nov 4, 2026 | FDA |
PeekMed webK262667 | Peek Health, S.A. | 510(k) clearance | Nov 4, 2026 | FDA |
CINA-Aneurysm+K262147 | AVICENNA.AI | 510(k) clearance | Oct 19, 2026 | FDA |
Ligence HeartK261733 | UAB Ligence | 510(k) clearance | Oct 7, 2026 | FDA |
QGuideCT (1.0)K260523 | Medis Medical Imaging Systems BV | 510(k) clearance | Oct 5, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Deep Reasoning Ai, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Sarasota, FL
Sources and methodology
- Original FDA record: K262134
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

